SYNACT — SynAct Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK908.29m
- SEK894.99m
Brief: SynAct Pharma Appoints Björn Westberg As CFO
Brief: SynAct Pharma Q1 Adj. Loss per Share at EPS SEK 1.59
Brief: SynAct Pharma Appoints Torbjørn Bjerke As New CEO
Brief: SynAct Pharma Affiliate TXP Pharma Gets Granted Patent In Canada
Brief: Synact Pharma CFO Patrik Renblad Resigns
Brief: SynAct Pharma's COO Sells Shares To Cover Tax On Holdings
Brief: SynAct Pharma To Acquire TXP Pharma For SEK 136 Mln
Brief: Synact Pharma Carries Out Directed Share Issue Of SEK 80 Mln
Brief: Synact Pharma Q3 Loss After Tax At SEK 23.9 Mln
Brief: SynAct Pharma Receives IND Clearance From FDA
Brief: SynAct Pharma: Approval Of Amended Study Protocol For Phase 2a Study In iMN
Brief: SynAct Says CTA Approves For Phase 2B Study Expand
Brief: Synact Pharma Q2 Loss After Tax Rises To SEK 24.8 Mln
Brief: Synact Pharma Improves Design Of Ongoing Phase 2A Study In iMN
Brief: Synact Pharma Recieves Pre-IND Response From The U.S. FDA
Brief: Synact Pharma Announces Outcome Of Rights Issue
Brief: Synact Pharma Reports Top-Line Results From Phase 2A Study Of AP1189 In Early Rheumatoid Arthritis Patients Experiencing Severe Disease Activity
Brief: Synact Pharma Q4 Pretax Loss Narrows To SEK 9.8 Million
Brief: SynAct Explores Conditions For Carrying Out Directed Share Issue